dc.contributor.author
Collettini, Federico
dc.contributor.author
Elkilany, Aboelyazid
dc.contributor.author
Seta, Marta Della
dc.contributor.author
Steffen, Ingo G.
dc.contributor.author
Collettini, Jasmin Maya
dc.contributor.author
Penzkofer, Tobias
dc.contributor.author
Schmelzle, Moritz
dc.contributor.author
Denecke, Timm
dc.date.accessioned
2024-07-23T08:10:54Z
dc.date.available
2024-07-23T08:10:54Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/44292
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-44003
dc.description.abstract
The routine use of dynamic-contrast-enhanced MRI (DCE-MRI) of the liver using hepatocyte-specific contrast agent (HSCA) as the standard of care for the study of focal liver lesions is not widely accepted and opponents invoke the risk of a loss in near 100% specificity of extracellular contrast agents (ECA) and the need for prospective head-to-head comparative studies evaluating the diagnostic performance of both contrast agents. The Purpose of this prospective intraindividual study was to conduct a quantitative and qualitative head-to-head comparison of DCE-MRI using HSCA and ECA in patients with liver cirrhosis and HCC. Twenty-three patients with liver cirrhosis and proven HCC underwent two 3 T-MR examinations, one with ECA (gadoteric acid) and the other with HSCA (gadoxetic acid). Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), wash-in, wash-out, image quality, artifacts, lesion conspicuity, and major imaging features of LI-RADS v2018 were evaluated. Wash-in and wash-out were significantly stronger with ECA compared to HSCA (P < 0.001 and 0.006, respectively). During the late arterial phase (LAP), CNR was significantly lower with ECA (P = 0.005), while SNR did not differ significantly (P = 0.39). In qualitative analysis, ECA produced a better overall image quality during the portal venous phase (PVP) and delayed phase (DP) compared to HSCA (P = 0.041 and 0.008), showed less artifacts in the LAP and PVP (P = 0.003 and 0.034) and a higher lesion conspicuity in the LAP and PVP (P = 0.004 and 0.037). There was no significant difference in overall image quality during the LAP (P = 1), in artifacts and lesion conspicuity during the DP (P = 0.078 and 0.073) or in the frequency of the three major LI-RADS v2018 imaging features. In conclusion, ECA provides superior contrast of HCC-especially hypervascular HCC lesions-in DCE-MR in terms of better perceptibility of early enhancement and a stronger washout.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Carcinoma, Hepatocellular
en
dc.subject
Chelating Agents
en
dc.subject
Gadolinium DTPA
en
dc.subject
Liver Cirrhosis
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
18583
dcterms.bibliographicCitation.doi
10.1038/s41598-022-23397-1
dcterms.bibliographicCitation.journaltitle
Scientific Reports
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
12
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36329107
dcterms.isPartOf.eissn
2045-2322